AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28490648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, meloxicam and gabapentin (AMG)
Number of subjects: 0
Study 25485880 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen and meloxicam
Number of subjects: 0
Study 25485880 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen and gabapentin
Number of subjects: 0
Study 25485880 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam and gabapentin
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: All four analgesic regimens
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough-evoked pain
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at rest, during sitting and peak expiration
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid consumption
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak expiratory flow rate
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed up and go test (TUG)
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Brief Pain Inventory (mBPI)
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and TUG correlation
Number of subjects: 0
Study 25485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and activity interference correlation
Number of subjects: 0
Study 23246175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified corn‐soy blended flour (CSB++)
Number of subjects: 409
Study 23246175 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy ready‐to‐use supplementary food (RUSF)
Number of subjects: 409
Study 23246175 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy/whey ready‐to‐use supplementary food (RUSF)
Number of subjects: 409
Study 23246175 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusing food
Number of subjects: 409
Study 20825879 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced electrolyte solution (BES)
Number of subjects: 45
Study 20825879 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 45
Study 19950733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol
Number of subjects: 60
Study 19950733 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with 1 MAC sevoflurane
Number of subjects: 60
Study 17937086 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg of tinzaparin sodium daily (Group A)
Number of subjects: 62
Study 17937086 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of aspirin daily (Group B)
Number of subjects: 62
Study 14624187 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (300 mg/d)
Number of subjects: 150
Study 14624187 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (60 mg/d)
Number of subjects: 150
Study 10532607 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL)
Number of subjects: 41
Study 8610735 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with intravenous gadolinium contrast and manual mixing of the diffused contrast
Number of subjects: 5
Study 8610735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach for knee arthrocentesis
Number of subjects: 5
Study 1744486 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cooling of the nailfold capillaries in patients with Crohn's disease
Number of subjects: 35
Study 1744486 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 35
Study 1744486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravital microscopy of nailfold capillaries in patients with Crohn's disease
Number of subjects: 35
Study 6339029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis
Number of subjects: 53
Study 6339029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 31914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic brief intervention to reduce alcohol misuse
Number of subjects: 0
Study 31914971 — intervention group
Group type: COMPARATOR
Intervention: Time-and attention-matched control
Number of subjects: 0
Study 31355323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg weekly
Number of subjects: 82
Study 31355323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg weekly
Number of subjects: 82
Study 31355323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg weekly (after relapse on 0.2 g/kg)
Number of subjects: 82
Study 31355323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg weekly (after dose reduction from 0.4 g/kg)
Number of subjects: 82
Study 31355323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 82
Study 28148629 — intervention group
Group type: EXPERIMENTAL
Intervention: PR fampridine (open-label)
Number of subjects: 53
Study 28148629 — intervention group
Group type: COMPARATOR
Intervention: PR fampridine (double-blind controlled)
Number of subjects: 53
Study 25454965 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-led (SL) group
Number of subjects: 12
Study 25454965 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led group
Number of subjects: 12
Study 23838107 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 1148
Study 23838107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Revascularization
Number of subjects: 1148
Study 21270384 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA supplementation
Number of subjects: 22
Study 21270384 — intervention group
Group type: COMPARATOR
Intervention: n‐6 PUFAs
Number of subjects: 22
Study 19811112 — intervention group
Group type: EXPERIMENTAL
Intervention: EFF1009 (medical food emulsion)
Number of subjects: 21
Study 19811112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (emulsion)
Number of subjects: 21
Study 16293341 — intervention group
Group type: EXPERIMENTAL
Intervention: MELANOTAN (NDP‐MSH)
Number of subjects: 77
Study 15201244 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 34
Study 15201244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10623701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide 200 mg/d for 28 days before surgery
Number of subjects: 30
Study 10623701 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills for 28 days before surgery
Number of subjects: 30
Study 9186211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Number of subjects: 33
Study 9186211 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 33
Study 1364188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition via fine-needle catheter jejunostomy
Number of subjects: 12
Study 1364188 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 12
Study 3966742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy
Number of subjects: 203
Study 3966742 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal oxygen therapy
Number of subjects: 203
Study 31690831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (lapatinib 1000 mg daily; vinorelbine 20 mg/m2 D1, D8 q3w)
Number of subjects: 149
Study 31690831 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2 D1, D8 q3w)
Number of subjects: 149
Study 31690831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine
Number of subjects: 149
Study 31690831 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 149
Study 29956458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-specific and nutrition-sensitive interventions
Number of subjects: 153
Study 29956458 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal morbidity
Number of subjects: 153
Study 29956458 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of ideal diet during pregnancy
Number of subjects: 153
Study 29956458 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of optimal foods for supporting healthy pregnancies
Number of subjects: 153
Study 28713059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fox's single pentagon technique
Number of subjects: 50
Study 28713059 — intervention group
Group type: COMPARATOR
Intervention: Modified Crawford double triangle technique
Number of subjects: 50
Study 25088067 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine BDP/FF NEXThaler(®) 100/6 μg bid
Number of subjects: 754
Study 25088067 — intervention group
Group type: COMPARATOR
Intervention: Extrafine BDP/FF pMDI 100/6 μg bid
Number of subjects: 754
Study 25088067 — intervention group
Group type: COMPARATOR
Intervention: Non-extrafine BDP DPI 100 μg bid
Number of subjects: 754
Study 23123362 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effect
Number of subjects: 0
Study 23123362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 0
Study 21037469 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine-dobutamine
Number of subjects: 30
Study 21037469 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 30
Study 19115650 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% levobupivacaine (3.3 ml bolus on demand, 5 mg/hour background infusion)
Number of subjects: 60
Study 19115650 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (1 ml bolus on demand, 5 mg/hour background infusion)
Number of subjects: 60
Study 16804151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 46
Study 16804151 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg each night)
Number of subjects: 46
Study 16804151 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 46
Study 14585898 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 mm mini-hysteroscope (group B)
Number of subjects: 200
Study 14585898 — intervention group
Group type: COMPARATOR
Intervention: 5 mm traditional hysteroscope (group A)
Number of subjects: 200
Study 10903050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural morphine
Number of subjects: 29
Study 10903050 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural morphine
Number of subjects: 29
Study 9294496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2 receptor agonist)
Number of subjects: 6
Study 9294496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8375125 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine once daily
Number of subjects: 12
Study 3760403 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite (K2S2O5, 1 mg/ml) skin testing
Number of subjects: 53
Study 3760403 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐blind oral provocative challenge tests with K2S2O5 (1, 5, 10, 25, and 50 mg)
Number of subjects: 53
Study 3760403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 53
Study 30291414 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-muscular approach (TQL)
Number of subjects: 54
Study 30291414 — intervention group
Group type: COMPARATOR
Intervention: Intra-muscular approach (IQL)
Number of subjects: 54
Study 27242201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral asymmetric decubitus posture
Number of subjects: 322
Study 27242201 — intervention group
Group type: COMPARATOR
Intervention: Dorsal recumbent posture (Control)
Number of subjects: 322
Study 24616448 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 1,500 mg in beverage form
Number of subjects: 201
Study 24616448 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 201
Study 24616448 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 201
Study 23739654 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×‐RDA (1.6 g kg(‐1) d(‐1))
Number of subjects: 39
Study 23739654 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×‐RDA (2.4 g kg(‐1) d(‐1))
Number of subjects: 39
Study 23739654 — intervention group
Group type: COMPARATOR
Intervention: RDA (0.8 g kg(‐1) d(‐1))
Number of subjects: 39
Study 20714273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based VCT
Number of subjects: 7184
Study 20714273 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based VCT
Number of subjects: 7184
Study 18422711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) treatment, 5% sodium fluoride, applied twice per year
Number of subjects: 1275
Study 18422711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 1275
Study 17120841 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing spatial frequency of elements in the intersection area up to 10 cycles deg(‐1)
Number of subjects: 0
Study 17120841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from perceiving distinct colors to a perceptually uniform grey
Number of subjects: 0
Study 17120841 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of transparency with color discrimination
Number of subjects: 0
Study 12820852 — intervention group
Group type: EXPERIMENTAL
Intervention: DenOptix
Number of subjects: 433
Study 12820852 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiDent
Number of subjects: 433
Study 12820852 — intervention group
Group type: COMPARATOR
Intervention: Digora
Number of subjects: 433
Study 12820852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimax2
Number of subjects: 433
Study 12820852 — intervention group
Group type: COMPARATOR
Intervention: Orthophos Plus
Number of subjects: 433
Study 10795775 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of exercise intervention
Number of subjects: 125
Study 7867240 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day (increased to 100 mg/day based on response)
Number of subjects: 122
Study 7867240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-SR 90 mg b.i.d. (increased to 180 mg b.i.d. based on response)
Number of subjects: 122
Study 7867240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 2766902 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 23
Study 2766902 — intervention group
Group type: COMPARATOR
Intervention: No enteric-coated aspirin
Number of subjects: 23
Study 23793 — intervention group
Group type: EXPERIMENTAL
Intervention: Camazepam 30 mg per day for 20 days
Number of subjects: 40
Study 23793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31761418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG, n=75)
Number of subjects: 150
Study 31761418 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG, n=75)
Number of subjects: 150
Study 31761418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG)
Number of subjects: 150
Study 31761418 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 150
Study 30442714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg administered subcutaneously every 2 weeks
Number of subjects: 140
Study 30442714 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously every 2 weeks
Number of subjects: 140
Study 30442714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 140
Study 30442714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 27925657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g cefazolin
Number of subjects: 67
Study 27925657 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g cefazolin
Number of subjects: 67
Study 27925657 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g cefazolin
Number of subjects: 67
Study 26573454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quince syrup (0.6 cc/kg/day)
Number of subjects: 80
Study 26573454 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (1 cc/kg/day)
Number of subjects: 80
Study 23949147 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 108
Study 21922528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (KGF)
Number of subjects: 100
Study 21922528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (low dose 240μg/kg)
Number of subjects: 100
Study 21922528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (day 30 ALC >600 ×106/L)
Number of subjects: 100
Study 21922528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18192900 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine daily for 54 weeks
Number of subjects: 110
Study 18192900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18192900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 110
Study 16494645 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac potassium sachets (50 mg)
Number of subjects: 184
Study 16494645 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac potassium tablets (50 mg)
Number of subjects: 184
Study 16494645 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 184
Study 14664680 — intervention group
Group type: EXPERIMENTAL
Intervention: New metrically comparable effect-size measures and estimators for multifactor designs
Number of subjects: 0
Study 14664680 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance-preservation model and variance-reduction model
Number of subjects: 0
Study 14664680 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical test for checking the validity of model assumptions
Number of subjects: 0
Study 10784227 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg daily for 7 days
Number of subjects: 7
Study 10784227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10784227 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Quinapril vs Placebo
Number of subjects: 7
Study 26630717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentrust toothbrush
Number of subjects: 57
Study 26630717 — intervention group
Group type: COMPARATOR
Intervention: Oral-B P35 toothbrush
Number of subjects: 57
Study 26630717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 57
Study 8466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 12.5 micrograms
Number of subjects: 24
Study 8466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 24
Study 8466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 24
Study 8466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 24
Study 8466097 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 200 micrograms
Number of subjects: 24
Study 8466097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3485071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-gel (pH 3.5, 5 ml) inserted into the vagina daily for 7 days
Number of subjects: 62
Study 3485071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole, 500 mg twice daily for 7 days
Number of subjects: 62
Study 3485071 — intervention group
Group type: COMPARATOR
Intervention: Both lactate-gel and metronidazole
Number of subjects: 62
Study 30982368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) group
Number of subjects: 80
Study 30982368 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy pregnant women)
Number of subjects: 80
Study 29055611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mammographic services
Number of subjects: 538
Study 29055611 — intervention group
Group type: COMPARATOR
Intervention: Fixed facility
Number of subjects: 538
Study 27189020 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multimedia decision aid
Number of subjects: 261
Study 27189020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 261
Study 24675287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 30mg daily for one year
Number of subjects: 1716
Study 24675287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal A subtype
Number of subjects: 1716
Study 24675287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal B/HER2- subtype
Number of subjects: 1716
Study 24675287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal A and B subtypes
Number of subjects: 1716
Study 22499461 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers, including a self-administered exercise program and 10 g amino-acid supplementation.
Number of subjects: 102
Study 22499461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 102
Study 22499461 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers.
Number of subjects: 102
Study 22499461 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers (good compliers).
Number of subjects: 102
Study 20306357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level warning group
Number of subjects: 78
Study 20306357 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level warning group
Number of subjects: 78
Study 20306357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 20306357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwarned simulator group
Number of subjects: 78
Study 18634944 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 22